After Intersect ENT announced that its clinical study of the safety and efficacy of the company's drug-coated sinus balloon failed to meet its primary endpoint, William Blair analyst Brian Weinstein called the news "a disappointing and frustrating development," but also said he never viewed this product as core to to his Outperform thesis for the stock. His focus for Intersect is much more on execution and returning to growth by selling the PROPEL family of products, Weinstein tells investors. Noting that he will try to speak with management later today, Weinstein said that for now he thinks investors should assume this product does not contribute in any way to revenues. However, he still thinks PROPEL products and SINUVA remain underpenetrated opportunities.